Christian B. Dinneen-Long
Consejero General en GLYCOMIMETICS, INC. .
Cargos activos de Christian B. Dinneen-Long
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| GLYCOMIMETICS, INC. | Consejero General | 29/04/2019 | - |
| Secretario Corporativo | 29/04/2019 | - |
Historial de carrera de Christian B. Dinneen-Long
Antiguos cargos conocidos de Christian B. Dinneen-Long.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Consejero General | - | - |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Consejero General | - | - |
| Medimmune, Inc. | Consejero General | - | - |
Formación de Christian B. Dinneen-Long.
| Chicago-Kent College of Law | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 7 |
Operativa
| General Counsel | 4 |
| Corporate Secretary | 1 |
| Graduate Degree | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
| Medimmune, Inc. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |